Tredu. Expert Education. Smarter Trading.

Mastering Equity and Stock Trading, Cryptocurrency Investment, Digital Assets and Global Forex Market Analysis: The Ultimate Masterclass at Tredu

Gain access to expert-led courses, live market analysis, and educational webinars that turn complex concepts into actionable strategies.Learn how to trade smarter and join our community of successful traders, building sustained financial growth.

Tredu.com / By Tredu.com / 5.12.2025 / 15:01

U.S. Economic Strength to Boost Assets and Dollar, Fed Rate Cut Expected: BBH Insights

Tredu.com / By Tredu.com / 5.12.2025 / 15:01

Dollar Rises as Fed’s Powell Signals Patience on Interest Rates Amid Easing U.S.-China Trade Tensions

Tredu.com / By Tredu.com / 5.12.2025 / 15:01

Unemployment Gap Between Canada and the U.S. Widens in 2024

Tredu.com / By Tredu.com / 5.12.2025 / 15:01

U.S. Economic Strength to Boost Assets and Dollar, Fed Rate Cut Expected: BBH Insights

Tredu.com / By Tredu.com / 5.12.2025 / 15:01

Dollar Rises as Fed’s Powell Signals Patience on Interest Rates Amid Easing U.S.-China Trade Tensions

Tredu.com / By Tredu.com / 5.12.2025 / 15:01

Unemployment Gap Between Canada and the U.S. Widens in 2024

Tredu.com / By Tredu.com / 5.10.2025 / 15:01

SMALL FINANCE BUSINESSES ARE ENJOYING THIS!

Tredu.com / By Tredu.com / 5.9.2025 / 15:01

U.S.-China Trade Deal Paves Way for Dollar Recovery, but Continued Progress Needed

Tredu.com / By Tredu.com / 5.12.2025 / 15:01

Traders Doubt Full Implementation of Trump's Tariff Threats Despite March 4 Deadline

Tredu.com / By Tredu.com / 5.10.2025 / 15:01

SMALL FINANCE BUSINESSES ARE ENJOYING THIS!

Tredu.com / By Tredu.com / 5.9.2025 / 15:01

U.S.-China Trade Deal Paves Way for Dollar Recovery, but Continued Progress Needed

Tredu.com / By Tredu.com / 5.12.2025 / 15:01

Traders Doubt Full Implementation of Trump's Tariff Threats Despite March 4 Deadline

Gold from another angle

By Tredu.com

Tredu.com

UK inflation has not inspired Pound buying

By Tredu.com

Tredu.com

EUR/USD Elliott Wave technical analysis [video]

By Tredu.com

Tredu.com

EUR/USD Elliott Wave technical analysis [video]

By Tredu.com

Tredu.com

Gold from another angle

By Tredu.com

Tredu.com

UK inflation has not inspired Pound buying

By Tredu.com

Tredu.com

EUR/USD Elliott Wave technical analysis [video]

By Tredu.com

Tredu.com

EUR/USD Elliott Wave technical analysis [video]

By Tredu.com

Tredu.com

Financial News

Maintain market dominance with real-time updates and expert analysis.
Our educators provide focused coverage across stock trading, forex markets, and crypto investing. We translate the latest financial news into practical knowledge, empowering you to trade smarter and achieve superior execution.

US Gasoline Hits Four-Year High As Oil Surge Slams Drivers

US drivers are paying the highest gasoline prices in four years as oil climbs above $100 and the energy shock feeds straight into inflation fears.

News & Insights

Proprietary Trading Strategies and
Quantitative Analysis

Sharpen your execution skills and gain a decisive edge with in-depth insights delivered by our top trading educators. Explore proven trading strategies, anticipate current market trends, and leverage expert analysis specifically designed to support your trading education and accelerate your path to sustained market success.

Tredu Team | Insights

Strive, Inc. (Nasdaq: ASST) Financial Overview and Cryptocurrency Ventures

Strive, Inc. (NASDAQ:ASST) has accumulated 13,628 bitcoins since its public listing, showcasing significant activity in the cryptocurrency market. The company reported an EPS of -$0.02 and revenue of $1.67 million for the quarter, aligning with estimates. Strive's financial ratios indicate strong liquidity and efficient cash flow conversion, despite challenges such as a negative earnings yield. Strive, Inc. (Nasdaq: ASST) is a company that has recently made headlines with its financial results. Known for its involvement in the cryptocurrency market, Strive has accumulated a significant amount of bitcoins since its public listing in September 2025. The company has gathered 13,628 bitcoins through various activities, including acquisitions and capital market ventures. On March 19, 2026, Strive reported its earnings, revealing an earnings per share (EPS) of -$0.02, which matched the estimated EPS. The company's revenue was $1.67 million, aligning perfectly with the estimated revenue. Despite these figures, Strive's financial activities in the cryptocurrency market have been noteworthy. In Q4 2025, the company achieved a Bitcoin yield of 22.2%, generating a Bitcoin gain of 1,305 BTC, translating to a dollar gain of $114.3 million. In the first quarter of 2026, Strive continued its momentum with a quarter-to-date Bitcoin yield of 13.8% as of March 17, 2026. The company generated a Bitcoin gain of 1,050 BTC, resulting in a dollar gain of $78.2 million. As of March 17, 2026, Strive's cash and cash equivalents stood at $83.7 million, showcasing its strong liquidity position. Strive's financial ratios provide further insight into its operations. The price-to-sales ratio of approximately 14.66 indicates that investors are willing to pay $14.66 for every dollar of sales. The enterprise value to operating cash flow ratio of about 0.74 suggests efficient cash flow conversion. The low debt-to-equity ratio of 0.024 reflects minimal reliance on debt financing, while a current ratio of 6.66 indicates strong liquidity. However, Strive faces challenges with a negative earnings yield of -12.94% and a negative price-to-earnings ratio of -0.077, indicating current losses. Despite these challenges, Strive's strategic focus on cryptocurrency and its strong liquidity position may provide opportunities for future growth.

Tredu Team | Insights

NRx Pharmaceuticals (NRXP) Q4 2025 Earnings & Financial Health Analysis

NRx Pharmaceuticals, Inc. (NRXP) Earnings and Financial Challenges Overview NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) is a clinical-stage biopharmaceutical company focused on developing treatments for depression, PTSD, and suicide prevention. The company is expected to release its Q4 2025 earnings (and potentially full-year 2025 results) around mid-to-late March 2026. Analyst estimates for the upcoming quarterly report vary across sources, but recent consensus points to an expected loss per share of approximately -$0.09 and projected revenue of around $7.53 million. Recent company announcement indicates a conference call on March 24, 2026, at 8:00 AM ET to discuss full-year 2025 financial results and provide a corporate update on drug development and the HOPE Therapeutics clinical network. This aligns with the company's mission to improve patient lives through innovative treatments. Despite these efforts, NRXP faces significant financial challenges as a pre-commercial biotech with limited revenue to date. The company has a negative trailing P/E ratio (around -1.07), confirming it is not currently profitable. The price-to-sales (P/S) ratio is very high at approximately 135–138. The enterprise value to sales ratio is even higher, recently reported around 258–264, underscoring the elevated valuation relative to current revenue. The enterprise value to operating cash flow ratio remains negative (consistent with ongoing cash burn), highlighting difficulties in generating positive cash flow from operations. NRXP's financial health is strained by a deeply negative earnings yield (implied by the negative P/E and large losses) and negative shareholders' equity (leading to a negative book value per share of around -$0.93). The debt-to-equity ratio is effectively near zero, but the company carries minimal traditional debt. The current ratio of 0.29 (as of the most recent quarter) indicates potential liquidity concerns, as current assets may not sufficiently cover short-term liabilities without additional financing or revenue growth.

Tredu Team | Insights

4D Molecular Therapeutics Q4 2025 Earnings Exceed Expectations

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Earnings Report Highlights 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) reported Q4 2025 EPS of $0.43, significantly outperforming the Zacks Consensus Estimate of a loss of -$0.53 per share (a +180.75% earnings surprise). Revenue for Q4 2025 (ending December 31, 2025) was $85.09 million, surpassing expectations by approximately 147.86% (primarily driven by recognition of an $85 million upfront collaboration payment from Otsuka Pharmaceutical in the Asia-Pacific region for 4D-150). 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is a biotechnology company focused on developing gene therapy products using its targeted vector evolution platform. It operates in the Zacks Medical - Drugs industry and competes with other firms in the gene therapy space. The company released its full-year 2025 financial results on March 18, 2026 (covering the quarter ending December 31, 2025). Analysts had estimated an EPS loss of approximately -$0.53 and revenue of around $30.9 million for Q4. In the recent report, FDMT delivered a strong quarterly EPS of $0.43, a remarkable turnaround from the expected loss and prior periods. This was largely due to one-time collaboration revenue. Full-year 2025 results showed a narrowed net loss of $140 million (or -$2.42 per diluted share), improved from $161 million (or -$2.98) in 2024. Revenue for full-year 2025 was $85 million (almost entirely from the Q4 collaboration). The Q4 revenue beat highlights growth potential from partnerships, though sustainability depends on pipeline progress and future milestones. The company maintains a strong balance sheet: low debt-to-equity ratio (~0.042), high current ratio (~9.39), and $514 million in cash, cash equivalents, and marketable securities as of December 31, 2025 (providing runway at least into the second half of 2028). These metrics reflect prudent financial management during its growth-focused phase.

Tredu Team | Insights

Strive, Inc. (Nasdaq: ASST) Financial Overview and Cryptocurrency Ventures

Tredu Team | Insights

NRx Pharmaceuticals (NRXP) Q4 2025 Earnings & Financial Health Analysis

Tredu Team | Insights

4D Molecular Therapeutics Q4 2025 Earnings Exceed Expectations

Technology-Powered Access to
Elite Trading Education

Comprehensive Trading Courses - tredu.com

Professional Trading Courses

Explore our meticulously selected curriculum of comprehensive trading courses sourced from trusted, proven educators. Master execution across Forex, Crypto and Stock Trading, ensuring your learning is guided only by instructors with verified, hands-on market experience.

Real-Time Trading Insights

Stay ahead of market movements with real-time analysis and actionable trading insights delivered by our top educators. Master the art of trading by directly following expert breakdowns across Forex, Cryptocurrency, and Stock Markets, ensuring you capitalize on every opportunity.

Interactive Trading Community

Access our dynamic interactive community, a growing network dedicated to excellence. Engage directly with fellow learners and top trading educators to accelerate your development. Pose critical questions, share advanced strategies, and master how to trade within a high-value, collaborative environment designed for sustained success.

Educators Hub

Discover our exclusive Educators Hub and connect with a vetted network of certified trading educators ready to guide your progress. Whether you are starting your journey or seeking to level up existing skills, Tredu ensures you are paired with the right mentor to accelerate your trading mastery.